Penn, whose comeback only at that month’s UFC 199 was derailed, stated he was clueless that IV rehydration was banned year-round after acknowledging his utilisation of the method throughout a March 21 out-of-competition drug test carried out by USADA. The UFC’s anti-doping policy forbids using an IV more than 50 mL on the six-hour period.
Here’s USADA’s full statement:
Which means Penn (16-10-1 MMA, 12-9-1 UFC) is going to be qualified to battle on September 25, clearing him from the preferred booking at UFC 205, that takes place November. 12 at New You are able to City’s Madison Square Garden. Penn on Sunday known as out his two-time opponent, former welterweight champion Georges St-Pierre (23-2 MMA 19-2 UFC).
UFC anti-doping partner USADA today introduced a six-month suspension for UFC Hall of Famer B.J. Penn, retroactive towards the March 25 date he accepted utilizing a banned IV.
“I under your own accord revealed to USADA that in a non-fight period which i had an IV given underneath the proper care of a physician,” stated inside a statement published on his website. “The rule for IV usage had altered since my last fight within the UFC and it was not aware from the change and under your own accord revealed the data to USADA.
For additional around the UFC’s approaching schedule, browse the UFC Gossips portion of the site.
USADA conducts the entire year-round, independent anti-doping program for those UFC athletes. USADA is definitely an independent, non-profit, non-governmental agency whose sole mission would be to preserve the integrity of competition, inspire true sport, and safeguard the legal rights of fresh athletes. The anti-doping program operated by USADA for UFC athletes includes education, science and research, testing, and results management. Official UFC Anti-Doping Program information and athlete sources can be found at UFC.USADA.org.
Penn, 37, under your own accord revealed his utilisation of the intravenous infusion and fully cooperated with USADA’s analysis in to the conditions in reference to his breach. Underneath the UFC Anti-Doping Policy, the conventional duration of ineligibility might be reduced because of a person’s voluntary admission of the breach and/or pursuant for an research into the individual’s amount of fault for that breach. Here, after taking each of individuals factors into account, USADA figured that a 6-month duration of ineligibility was a suitable sanction underneath the rules for Penn’s breach.
Penn’s duration of ineligibility started on March 25, 2016, the date which he accepted his anti-doping policy breach to USADA.
Throughout an out-of-competition test on March 25, 2016, Penn declared using an intravenous infusion of the non-prohibited substance. A subsequent analysis by USADA says the intravenous infusion received by Penn was given inside a volume more than 50 mL inside a 6 hour period. Underneath the UFC Anti-Doping Policy, intravenous infusions inside a volume more than 50 mL inside a 6 hour period are prohibited, aside from individuals legitimately received throughout hospital admissions, surgical methods or clinical research. Intravenous infusions received in almost any other setting require an authorized Therapeutic Use Exemption (TUE).
Penn known as for any grapple with St-Pierre at lightweight following the ex-champion stated he could easily compete at 155 pounds. St-Pierre, whose comeback seems imminent, is the owner of two wins over Penn at UFC 58 and UFC 94.
USADA introduced today that Jay Dee (“BJ”) Penn of Hilo, Hawaii, a sports athlete within the UFC, has recognized a 6-month sanction to have an anti-doping policy breach for his utilization of a prohibited method.
By: Steven Marrocco June 27, 2016 4:05 pm
Inside a statement published today on USADA’s website, the 3rd-party administrator stated Penn’s “voluntary” disclosure and cooperation factored into his six-month suspension. He faced a 2-year term for breaking the UFC’s anti-doping policy, which states using an IV more than 50 mL on the six-hour period is forbidden, “except for individuals legitimately received throughout hospital admissions, surgical methods or clinical research. Intravenous infusions received in almost any other setting require an authorized therapeutic use exemption (TUE).”